End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.
摘要:
Purpose: Use of 2[F-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in post-chemotherapy response assessment in follicular lymphoma is still a controversial issue. Here, we conducted the first systematic review and meta-analysis to determine the predictive value of FDG-PET in predicting outcome after chemotherapy of follicular lymphoma.Experimental Design: Comprehensive literature search in Ovid-MEDLINE and EMBASE databases was performed to identify studies which evaluate predictive value of end-therapy PET and/or computed tomography (CT) in patients with follicular lymphoma. To quantitatively compare the predictive value of PET and CT, pooled hazard ratios (HRs) comparing progression-free survival (PFS) between patients with positive and negative results were adopted as the primary indicators for meta-analysis. To explore the efficiency in determining complete remission (CR), pooled CR rates of PET-and CT-based response criteria were calculated. Pooling of these parameters was based on the random-effects model.Results: Review of 285 candidate articles identified eight eligible articles with a total of 577 patients for qualitative review and meta-analysis. The pooled HRs of end-therapy PET and CT were 5.1 [95% confidence interval (CI), 3.7-7.2] and 2.6 (95% CI, 1.2-5.8), respectively, which implies that PET is more predictive of PFS after chemotherapy than CT. The pooled CR rates of PET-and CT-based response criteria were 75% (95% CI, 70-79%) and 63% (95% CI, 53-73%), respectively, which implies that PET is more efficient in distinguishing CR (without residual disease) from other states with residual disease. In addition, qualitative systematic review indicates the same findings.Conclusions: Consistent evidence favoring PET-based treatment assessment should be considered in the management of patients with follicular lymphoma. Clin Cancer Res; 19(23); 6566-77. (C) 2013 AACR.
展开
关键词:
NON-HODGKINS-LYMPHOMA FOLLOW-UP FDG-PET Y-90-IBRITUMOMAB TIUXETAN MALIGNANT-LYMPHOMA PREDICTIVE-VALUE F-18-FDG PET/CT DES LYMPHOMES RADIOIMMUNOTHERAPY MULTICENTER
DOI:
10.1158/1078-0432.CCR-13-1511
被引量:
年份:
2013
通过文献互助平台发起求助,成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用!